What do systematic reviews say?

Subdiaphragmatic intraperitoneal local anaesthetic vs control

• Interventions to reduce shoulder pain following gynaecological laparoscopic procedures 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 50 participants
  Low

Subdiaphragmatic intraperitoneal local anaesthetic vs control

• Interventions to reduce shoulder pain following gynaecological laparoscopic procedures 2019 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 165 participants
  GRADE not reported

Subdiaphragmatic intraperitoneal local anaesthetic vs control

• Interventions to reduce shoulder pain following gynaecological laparoscopic procedures 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 129 participants
  Low

Thermotherapy one session (at 50 ºC for 30 seconds) vs meglumine antimoniate (20 mg Sb5/kg/day

Thermotherapy one session (at 50 ºC for 30 seconds) leads to lower complete cure, at least 3 months after the end of treatment compared with meglumine antimoniate (20 mg Sb5/kg/day (high certainty).

• Interventions for American cutaneous and mucocutaneous leishmaniasis 2020 · Cochrane Headline outcomes only
  RR 0.8 [0.68, 0.95]
  1 study · 292 participants
  High

Thermotherapy one session (at 50 ºC for 30 seconds) vs meglumine antimoniate (20 mg Sb5/kg/day

• Interventions for American cutaneous and mucocutaneous leishmaniasis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 292 participants
  High

Thermotherapy one session (at 50 ºC for 30 seconds) vs meglumine antimoniate (20 mg Sb5/kg/day

The review found no eligible studies for this question.

• Interventions for American cutaneous and mucocutaneous leishmaniasis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Beclometasone dipropionate (systemic corticosteroid) vs Placebo or no treatment

The review found no eligible studies for this question.

• Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes
  Table 1: 'Studies of these corticosteroids were not found or included in the review but are included here for completeness.' No trial of beclometasone dipropionate for RAS was identified.
  0 studies
  No studies found

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferoxamine

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 612 participants
  Very low

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferasirox (DFX)

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 390 participants
  Low

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferasirox (DFX)

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  1.54 [0.44, 5.39]
  1 study · 390 participants
  Very low

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferasirox (DFX)

It is very uncertain whether summary of findings: Comparison 3 ‐ deferiprone (DFP) changes total SAEs compared with deferasirox (DFX) (very low certainty).

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  RR 0.95 [0.46, 1.96]
  1 study · 390 participants
  Very low

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferasirox (DFX)

Summary of findings: Comparison 3 ‐ deferiprone (DFP) showed no clear difference in all‐cause mortality (n/N) compared with deferasirox (DFX) (low certainty).

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  RD 0
  1 study · 390 participants
  Low

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferasirox (DFX)

The review found no eligible studies for this question.

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferasirox (DFX)

The review found no eligible studies for this question.

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferoxamine

It is very uncertain whether summary of findings: Comparison 1 ‐ deferiprone (DFP) changes total reported SAEs (from therapy, disease, non‐adherence) compared with deferoxamine (DFO) (very low certainty).

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  RR 1.43 [0.83, 2.46]
  1 study · 228 participants
  Very low

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferoxamine

It is very uncertain whether summary of findings: Comparison 1 ‐ deferiprone (DFP) changes all‐cause mortality compared with deferoxamine (DFO) (very low certainty).

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  RR 0.47 [0.18, 1.21]
  3 studies · 376 participants
  Very low

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferoxamine

The review found no eligible studies for this question.

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferoxamine

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 1 participants
  Very low

Selective carious tissue removal (selective excavation, SE) vs Non-selective or complete carious tissue removal

Partial caries removal was reported to reduce pulp-exposure risk by 77% versus complete caries removal (RR 0.23; ungraded).

• Minimal intervention dentistry for managing carious lesions into dentine in primary teeth: an umbrella review. 2022 All outcomes

  12 months · Primary and permanent teeth combined (2 studies)
  RR 0.23 [0.08, 0.69]
  2 studies
  GRADE not reported

Selective carious tissue removal (selective excavation, SE) vs Non-selective or complete carious tissue removal

Partial caries removal reduced the reported risk of pulp exposure versus complete caries removal in primary teeth (RR 0.24; ungraded).

• Minimal intervention dentistry for managing carious lesions into dentine in primary teeth: an umbrella review. 2022 All outcomes

  12 months · Primary teeth
  RR 0.24 [0.06, 0.90]
  262 participants
  GRADE not reported